{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:04:35Z","timestamp":1767135875522,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd010501","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T00:00:00Z","timestamp":1428883200000}}],"reference-count":58,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010501.pub2","type":"journal-article","created":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T06:14:49Z","timestamp":1428905689000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia"],"prefix":"10.1002","volume":"2015","author":[{"given":"Adegoke Oloruntoba","family":"Adelufosi","sequence":"first","affiliation":[{"name":"Northern Regional Health Authority; Community Mental Health Program; 867 Thompson Drive South Thompson Manitoba Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olukayode","family":"Abayomi","sequence":"additional","affiliation":[{"name":"Ladoke Akintola University Teaching Hospital; Psychiatry; P.M.B 4007 Ogbomoso Oyo Nigeria 210214"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tunde Massey-Ferguson","family":"Ojo","sequence":"additional","affiliation":[{"name":"Neuropsychiatric Hospital; Clinicial Sciences (Resident Doctors Office); PMB 2002 ARO, Abeokuta, Ogun State Nigeria 234"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,4,13]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD010501.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1176\/appi.ajp.158.9.1511","article-title":"Vitamin B6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study","volume":"158","author":"Lerner","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD010501.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.4088\/JCP.v68n1103","article-title":"Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study","volume":"68","author":"Lerner","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"8-9","key":"10.1002\/14651858.CD010501.pub2-BIB0003|cit3","first-page":"592-6, 647","article-title":"Vitamin B6 ad-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders","volume":"142","author":"Miodownik","year":"2003","journal-title":"Harefuah"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0004|cit4","unstructured":"Greenberg WM A 12-week, double-blind, augmentation study of the effects of folic acid, B-12, and pyridoxine in lowering homocysteine levels and treating psychopathology and cognitive deficits in schizophrenia Stanley Foundation Research Programs 2003"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Lerner V Miodownik C Kaptsan A Cohen H Loewental U Kotler M Double-blind evaluation of Vitamin B6 vs Placebo in treatment of tardive dyskinesia European Neuropsychopharmacology 1999 S369","DOI":"10.1016\/S0924-977X(99)80579-3"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0006|cit6","unstructured":"Lerner V Cohen H A double-blind, randomised, placebo-controlled, crossover study of the effects of vitamin B6 in 50 in-patients with tardive dyskinesia Stanley Foundation Research Institute 2002"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0007|cit7","first-page":"105","article-title":"Vitamin B-sub-6. The experience in treating psychotic symptoms and psychotropic drug-indced movement disorders","volume-title":"Psychology and Schizophrenia","author":"Lerner","year":"2007"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0008|cit8","unstructured":"Lerner V Vitamin B6 for tardive movement disorder Stanley Foundation Research Programs 2009"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0009|cit9","unstructured":"NCT00202280 Efficacy of treating first episode psychosis with folic acid, vitamin B12 and B6 in addition to antipsychotic medication http:\/\/www.clinicaltrials.gov.\/ct2\/show\/NCT00202280?term=NCT00202280&rank=1"},{"issue":"1","key":"10.1002\/14651858.CD010501.pub2-BIB0010|cit10","first-page":"9","article-title":"Pyridoxine for drug induced dyskinesia. A placebo- controlled randomised cross-over trial","volume":"44","author":"Venegas","year":"2006","journal-title":"Revista Chilena de Neuropsiquiatrica"},{"issue":"9","key":"10.1002\/14651858.CD010501.pub2-BIB0011|cit11","first-page":"558","article-title":"The effect of huangqi injection in the treatment of tardive neuropathy caused by acute organophosphorus insecticide poisoning","volume":"21","author":"Xiao","year":"2002","journal-title":"Herald of Medicine"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0012|cit12","unstructured":"NCT00917293 Safety and efficacy of avastrem (pyridoxal 5' -phosphate) in the treatment of tardive dyskinesia http:\/\/www.clinicaltrials.gov 2009"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S0006-3223(97)00027-9","article-title":"Long-term treatment effects of vitamin E for tardive dyskinesia","volume":"43","author":"Adler","year":"1998","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0015|cit15","unstructured":"American Psychiatric Association Tardive dyskinesia: a task force report of the American Psychiatric Association Washington DC 1992"},{"issue":"10","key":"10.1002\/14651858.CD010501.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.4088\/JCP.v69n1008","article-title":"Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study","volume":"69","author":"Ascher-Svanum","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12888-014-0280-1","article-title":"Movement disorders in neuroleptic-na\u00efve patients with schizophrenia spectrum disorders","volume":"14","author":"Ayehu","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0018|cit18","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-079035-7.50021-X","article-title":"The side-effects of antipsychotic drugs","volume-title":"Antipsychotic Drugs and their Side-effects","volume":"I","author":"Barnes","year":"1993"},{"issue":"4","key":"10.1002\/14651858.CD010501.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s004060050039","article-title":"Clozapine efficacy in tardive dyskinesia in schizophrenic patients","volume":"248","author":"Bassitt","year":"1998","journal-title":"European Archives Psychiatry and Clinical Neuroscience"},{"issue":"4","key":"10.1002\/14651858.CD010501.pub2-BIB0020|cit20","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1600-0447.1996.tb09835.x","article-title":"Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia","volume":"94","author":"Browne","year":"1996","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"10","key":"10.1002\/14651858.CD010501.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4088\/JCP.v62n1004","article-title":"Treatment of tardive dyskinesia with donepezil: A pilot study","volume":"62","author":"Caroff","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0023|cit23","first-page":"546\u201365","article-title":"Neuroleptic-induced extrapyramidal syndromes and tardive dyskinesia","volume-title":"Schizophrenia","author":"Casey","year":"1995"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"313\u20139","DOI":"10.1001\/archpsyc.1996.01830040049009","article-title":"Incidence and correlates of tardive dyskinesia in first episode of schizophrenia","volume":"53","author":"Chakos","year":"1996","journal-title":"Archives of General Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD010501.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the Extrapyramidal Symptom Rating Scale (ESRS)","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"12","key":"10.1002\/14651858.CD010501.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0027|cit27","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"issue":"1","key":"10.1002\/14651858.CD010501.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1-2","key":"10.1002\/14651858.CD010501.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0920-9964(97)82782-X","article-title":"The effect of nifedipine on tardive dyskinesia: a double blind study in eighteen patients","volume":"24","author":"Fay-McCarthy","year":"1997","journal-title":"Schizophrenia Research"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD010501.pub2-BIB0030|cit30","first-page":"10","article-title":"Prevalence of spontaneous dyskinesia in schizophrenia","volume":"61","author":"Fenton","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0031|cit31","unstructured":"Fleiss JL The crossover study. The design and analysis of clinical experiments Chichester: John Wiley & Sons 1984"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0033|cit33","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0034|cit34","doi-asserted-by":"crossref","unstructured":"Hoenders R Bartels-Velthuis A Vollbehr N Bruggeman R Knechtering R de Jong J Natural medicines in schizophrenia: A systematic review Journal of Alternative and Complementary Medicine 2014 A79 80","DOI":"10.1089\/acm.2014.5209.abstract"},{"issue":"1","key":"10.1002\/14651858.CD010501.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0036|cit36","first-page":"254\u20138","article-title":"Integrating incidence and prevalence of tardive dyskinesia","volume":"22","author":"Kane","year":"1986","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) forschizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD010501.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0278-5846(03)00171-4","article-title":"Tardive dyskinesia in Chinese inpatients with chronic schizophrenia","volume":"27","author":"Leung","year":"2003","journal-title":"Progress in Neuropharmacology and Biological Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010501.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/10401230591002002","article-title":"History of the discovery and clinical introduction of chlorpromazine","volume":"17","author":"Lopez-Munoz","year":"2005","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010501.pub2-BIB0041|cit41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000209","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","author":"McGrath","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/WNF.0b013e3181506623","article-title":"Pyridoxal plasma level in schizophrenic and schizoaffective patients with and without tardive dyskinesia","volume":"31","author":"Miodownik","year":"2008","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD010501.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/10401230500464737","article-title":"Focus on lower risk of tardive dyskinesia with atypical antipsychotics","volume":"18","author":"Nasrallah","year":"2006","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1345\/aph.1C460","article-title":"Melatonin for the treatment of tardive dyskinesia","volume":"37","author":"Nelson","year":"2003","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1176\/jnp.2008.20.3.317","article-title":"Predictors of abnormal involuntary movement in an African schizophrenia population","volume":"20","author":"Niehaus","year":"2008","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1192\/bjp.155.2.253","article-title":"Depression-dependent exacerbation of tardive dyskinesia","volume":"155","author":"Sachdev","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM198308253090801","article-title":"Sensory neuropathy from pyridoxine abuse - A new megavitamin syndrome","volume":"309","author":"Schaumburg","year":"1983","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2008"},{"issue":"1","key":"10.1002\/14651858.CD010501.pub2-BIB0050|cit50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000206.pub2","article-title":"Calcium channel blockers for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010501.pub2-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000207","article-title":"Cholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Tammenmaa","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD010501.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.comppsych.2007.05.003","article-title":"Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study","volume":"48","author":"Tenback","year":"2007","journal-title":"Comprehensive Psychiatry"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/mds.25107","article-title":"Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis","volume":"27","author":"Teo","year":"2012","journal-title":"Movement Disorders"},{"issue":"10","key":"10.1002\/14651858.CD010501.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpsyc.1987.01800220077011","article-title":"Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality","volume":"44","author":"Waddington","year":"1987","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1176\/ajp.150.6.966","article-title":"Diabetes and development of tardive dyskinesia","volume":"150","author":"Woerner","year":"1993","journal-title":"American Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD010501.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/schbul\/18.4.701","article-title":"Gender differences in tardive dyskinesia: a critical review of the literature","volume":"18","author":"Yassa","year":"1992","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD010501.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/01.jcp.0000104912.75206.2b","article-title":"The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial","volume":"24","author":"Zhang","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD010501.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T08:54:14Z","timestamp":1714640054000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010501.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,4,13]]},"references-count":58,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010501.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,13]]}}}